Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MCKESSON CORPORATION

(MCK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/23/2021 11/24/2021 11/26/2021 11/29/2021 11/30/2021 Date
226.45(c) 226.02(c) 221.61(c) 223.27(c) 216.76(c) Last
1 007 480 867 876 504 728 734 575 1 348 442 Volume
+1.97% -0.19% -1.95% +0.75% -2.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 259 B - -
Net income 2022 2 244 M - -
Net Debt 2022 490 M - -
P/E ratio 2022 15,1x
Yield 2022 0,86%
Sales 2023 259 B - -
Net income 2023 2 686 M - -
Net cash position 2023 1 427 M - -
P/E ratio 2023 12,2x
Yield 2023 0,89%
Capitalization 33 095 M 33 095 M -
EV / Sales 2022 0,13x
EV / Sales 2023 0,12x
Nbr of Employees 67 500
Free-Float 55,2%
More Financials
Company
McKesson Corporation is focused distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools. The CompanyÔÇÖs segments include U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment provides distribution and logistics services for branded, generic, specialty, biosimilar, and... 
Sector
Drug Retailers
Calendar
11/30
More about the company
Ratings of McKesson Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about MCKESSON CORPORATION
11/30Walgreens to Buy Remaining Shares in GEHE-Alliance Healthcare JV from McKesson for Undi..
MT
11/30MCKESSON CORPORATION : Ex-dividend day for
FA
11/23INSIDER SELL : McKesson
MT
11/15Washington state, in $95 billion opioid trial, blames drug distributors for crisis
RE
11/14Washington seeks over $38 billion from opioid distributors
AQ
11/12INSIDER SELL : Mckesson
MT
11/12Factbox-J&J's legal liabilities as it plans to split
RE
11/09Oklahoma court overturns $465 mln opioid judgment against J&J
RE
11/08Credit Suisse Adjusts McKesson's Price Target to $230 from $224, Keeps Neutral Rating
MT
11/04INSIDER SELL : Mckesson
MT
11/04McKesson Corporation Opens New Pharmaceutical Distribution Center in Michigan
CI
11/03Ontada Names Sagran Moodley as Chief Innovation and Technology Officer
PU
11/03EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment for EGFR Exon20 Ins..
PU
11/03Deutsche Bank Lifts McKesson's Price Target to $279 From $261; Buy Rating Kept
MT
11/03Mizuho Securities Adjusts McKesson's Price Target to $229 From $210, Reiterates Neutral..
MT
More news
News in other languages on MCKESSON CORPORATION
11/23VENTE PAR DES INITIÉS : McKesson
11/12VENTE D'INITIÉS : Mckesson
11/01Les gains de McKesson au deuxième trimestre dépassent les prévisions de la Bourse ; les..
11/01HISTORIQUE DES RÉACTIONS AUX RÉSULTA : McKesson Corp, indicateur de suivi à 60,0%, sensibl..
11/01MÄRKTE USA/Gewinnmitnahmen nach Dow-Sprung über 36.000-Punktemarke
More news
Analyst Recommendations on MCKESSON CORPORATION
More recommendations
Chart MCKESSON CORPORATION
Duration : Period :
McKesson Corporation Technical Analysis Chart | MCK | US58155Q1031 | MarketScreener
Technical analysis trends MCKESSON CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 216,76 $
Average target price 250,69 $
Spread / Average Target 15,7%
EPS Revisions
Managers and Directors
Brian Scott Tyler Chief Executive Officer & Director
Britt J. Vitalone Chief Financial Officer & Executive Vice President
Edward A. Mueller Independent Chairman
Nancy Flores Chief Technology & Information Officer, EVP
Donald R. Knauss Independent Director
Sector and Competitors